down arrow

Kymera Therapeutics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5015751044
USD
66.23
1.96 (3.05%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
ADMA Biologics, Inc.
Prime Medicine, Inc.
Inhibrx, Inc.
Dianthus Therapeutics, Inc.
Immatics NV
Kymera Therapeutics, Inc.
Rayzebio, Inc.
Cogent Biosciences, Inc.
Apogee Therapeutics, Inc.
Replimune Group, Inc.
Axcella Health, Inc.
Why is Kymera Therapeutics, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate -234.21% of over the last 5 years
2
The company has declared negative results for the last 3 consecutive quarters
  • The company has declared negative results in Sep 24 after 3 consecutive negative quarters
  • NET SALES(Q) At USD 11.48 MM has Fallen at -22.04%
  • OPERATING CASH FLOW(Y) Lowest at USD -251 MM
  • INTEREST(HY) At USD 0.18 MM has Grown at 38.46%
3
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 40.45%, its profits have fallen by -60.9%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kymera Therapeutics, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Kymera Therapeutics, Inc.
41.19%
1.25
74.40%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
36.31%
EBIT Growth (5y)
-234.21%
EBIT to Interest (avg)
-158.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.57
Sales to Capital Employed (avg)
0.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.94
EV to EBIT
-9.53
EV to EBITDA
-9.81
EV to Capital Employed
7.88
EV to Sales
45.02
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-82.73%
ROE (Latest)
-30.64%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET PROFIT(HY)

Higher at USD -142.19 MM

CASH AND EQV(HY)

Highest at USD 1,128.6 MM

-29What is not working for the Company
NET SALES(Q)

At USD 11.48 MM has Fallen at -22.04%

OPERATING CASH FLOW(Y)

Lowest at USD -251 MM

INTEREST(HY)

At USD 0.18 MM has Grown at 38.46%

RAW MATERIAL COST(Y)

Grown by 11.74% (YoY

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.14 times

OPERATING PROFIT(Q)

Lowest at USD -82.47 MM

PRE-TAX PROFIT(Q)

Lowest at USD -76.61 MM

NET PROFIT(Q)

Lowest at USD -76.61 MM

EPS(Q)

Lowest at USD -0.95

Here's what is working for Kymera Therapeutics, Inc.
Cash and Eqv
Highest at USD 1,128.6 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Depreciation
Highest at USD 2.08 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Kymera Therapeutics, Inc.
Net Sales
At USD 11.48 MM has Fallen at -22.04%
over average net sales of the previous four periods of USD 14.72 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Interest
At USD 0.18 MM has Grown at 38.46%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Cash Flow
Lowest at USD -251 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit
Lowest at USD -82.47 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit
Lowest at USD -76.61 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Pre-Tax Profit
At USD -76.61 MM has Fallen at -27.22%
over average net sales of the previous four periods of USD -60.22 MM
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -76.61 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Net Profit
At USD -76.61 MM has Fallen at -27.22%
over average net sales of the previous four periods of USD -60.22 MM
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

EPS
Lowest at USD -0.95
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Debtors Turnover Ratio
Lowest at 2.14 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost
Grown by 11.74% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."